What is SLU-PP-915 Research Compound?

SLU-PP-915 Research Compound is a oral-format research product available from Royal Peptides. The listing provides its stated format, quantity, specifications and available batch documentation for qualified laboratory research.

What research category does SLU-PP-915 Research Compound belong to?

SLU-PP-915 Research Compound is categorized under oral-format research products. It may be examined in research involving the molecular and biochemical pathways described in the product specifications.

What research methods may involve SLU-PP-915 Research Compound?

Laboratory investigation of SLU-PP-915 Research Compound may consider compound identity, concentration and controlled laboratory design. Appropriate controls, validated procedures and qualified interpretation are essential.

How does SLU-PP-915 Research Compound compare with related research compounds?

SLU-PP-915 Research Compound may differ from other research compounds in oral formats in structure, targets, signaling profile and experimental application. Comparisons should be based on published literature and controlled laboratory design.

Is third-party testing available for SLU-PP-915 Research Compound?

Available purity, mass, identity, endotoxin or other batch documentation for SLU-PP-915 Research Compound may be reviewed on its product page or through the Royal Peptides COA library. Testing availability varies by product and batch.

What format is SLU-PP-915 Research Compound supplied in?

SLU-PP-915 Research Compound is supplied in the capsule or tablet format and quantity stated on the product page. Confirm the listed strength, count and packaging before ordering.

How should SLU-PP-915 Research Compound be stored?

Keep SLU-PP-915 Research Compound sealed, secured and protected from excessive heat, moisture and direct light. Follow the storage information displayed on the product page, packaging and applicable batch documentation.

Is SLU-PP-915 Research Compound intended for human consumption?

No. SLU-PP-915 Research Compound is offered strictly for laboratory and research use only. It is not intended for human consumption, medical treatment, diagnosis or veterinary use.

Batch documentation availableReview available analytical information for the selected research material.

Research Use Only Laboratory Research Materials

Royal Peptides products are offered exclusively for laboratory research, analytical, and scientific applications. Not for human or veterinary use.

01Research Product Information

Royal Peptides supplies compounds intended for controlled laboratory research and analytical applications.

For research and analytical use only
Not intended for human consumption or administration
Not intended for veterinary use
Not represented as a drug, medicine, or therapeutic product
Laboratory researchers are responsible for appropriate protocols and controls

Research Only Laboratory Material Analytical Use

02Lyophilized Product Format

Where applicable, Royal Peptides research materials are supplied in lyophilized form.

Lyophilization is a freeze-drying process used to remove moisture from material under controlled conditions.

Material appearance may differ between compounds and production lots
Lyophilized material may appear as a cake, film, or fragmented material
The quantity of visible material may appear small relative to vial size
Visual appearance alone does not establish identity or purity

03Storage & Laboratory Handling

Storage requirements may vary by compound, formulation, and production lot. Refer to the product label and available product-specific documentation.

Protect research materials from excessive heat
Limit unnecessary exposure to direct light and moisture
Keep containers securely closed when stored
Follow product-specific temperature requirements when provided
Use appropriate laboratory contamination-control procedures

04Packaging & Quality Documentation

Packaging components may vary slightly between production lots. This can include vial closures, cap styles, label positioning, and external packaging.

Check the product label and lot identifier before laboratory use
Inspect the vial and closure for visible shipping damage
Packaging design may differ between batches
Lot-specific analytical documentation may be available in our COA library

View COA Library

ROYAL RESEARCH CATALOG

SLU-PP-915 Research Compound

Research Material Batch Documentation Secure Checkout

Choose an option

10mg/50 caps
2.5mg/50caps
20mg/50caps
500mcg/100caps
5mg/50caps

Clear selection

PLEASE REVIEW BEFORE ORDERING Important Product Notice

10-VIAL KITS — VIALS ARE NOT INDIVIDUALLY LABELED
10-vial research kits are supplied without individual vial labels. Product and batch identification are provided with the kit packaging.

RECONSTITUTION MATERIALS
For reconstitution-related research, use Royal Peptides® Reconstitution Solution ↗ or a genuine manufacturer-sealed Hospira® / Pfizer® product where applicable.

SUPPORT NOTICE
Support may be limited when unverified third-party materials are used.

01Research focusedLaboratory research materials

02DocumentedAvailable batch information

03TrackedOrder fulfillment updates

Secure payment VISA link $ ₿

RESEARCH NOTICE

For laboratory and research purposes only.Not intended for human consumption, diagnostic use, therapeutic use, or administration to humans or animals.

View Documentation →

Pan-ERR Research • 2026 Reference

SLU-PP-915 Research Compound

SLU-PP-915 is a chemically distinct synthetic small-molecule pan-estrogen-related receptor agonist investigated across ERRα, ERRβ and ERRγ. Published preclinical research has examined its oral bioavailability, mitochondrial and metabolic signaling, ERR-regulated gene expression and exercise-associated biology.

Pan-ERR Agonist ERRα / ERRβ / ERRγ Small Molecule Orally Bioavailable in Mice Mitochondrial Research Research Use Only

Compound Class Synthetic Small Molecule

Research Targets ERRα / ERRβ / ERRγ

Pharmacology Pan-ERR Agonist

Research Status Preclinical

What Is SLU-PP-915?

SLU-PP-915 is an experimental synthetic small molecule identified during medicinal-chemistry research into potent agonists of the estrogen-related receptor family.

The compound belongs to a chemical series of 2,5-disubstituted thiophenes investigated for estrogen-related receptor activity. SLU-PP-915 contains a boronic-acid moiety and was characterized as a potent pan-ERR agonist with activity across ERRα, ERRβ and ERRγ.

SLU-PP-915 is not a peptide. It is a chemically distinct small-molecule research compound developed after earlier work involving experimental ERR agonists such as SLU-PP-332.

How Does SLU-PP-915 Work in Research Models?

Estrogen-related receptors are nuclear receptors involved in the transcriptional regulation of genes associated with cellular energy metabolism. SLU-PP-915 is used experimentally to investigate the effects of pharmacological activation of this receptor family.

SLU-PP-915

ERRα / ERRβ / ERRγ

ERR-Regulated Gene Expression

Metabolic & Mitochondrial Research

Published medicinal-chemistry research reported significant upregulation of established ERR target genes following experimental exposure to SLU-PP-915, including genes relevant to metabolic and exercise-associated signaling.

SLU-PP-915 Research Areas

SLU-PP-915 has been investigated across several interconnected areas of nuclear-receptor, metabolic and mitochondrial research.

Pan-ERR Signaling

Experimental investigation of agonist activity across estrogen-related receptors ERRα, ERRβ and ERRγ.

Mitochondrial Biology

Research involving ERR-regulated pathways associated with mitochondrial biogenesis, oxidative phosphorylation and cellular energetics.

Skeletal-Muscle Research

Preclinical investigation of ERR activation, muscle gene expression and biological responses associated with aerobic exercise.

Oral Activity

Later preclinical work demonstrated biological activity following oral administration of SLU-PP-915 in mouse models.

SLU-PP-915 and Oral Bioavailability

One of the most important research characteristics distinguishing SLU-PP-915 from the earlier SLU-PP-332 compound is its oral bioavailability in preclinical mouse research.

Published 2026 research characterized SLU-PP-915 as a chemically distinct ERR pan-agonist that maintained biological efficacy following oral administration in mice when systemic exposure was taken into account.

SLU-PP-332 Lacks oral bioavailability in the published model

    SLU-PP-915
    Oral bioavailability demonstrated in mice
  

Preclinical distinction: oral bioavailability or biological activity in mice does not establish human oral pharmacokinetics, efficacy, dosing or safety.

SLU-PP-915 Chemistry and Development

The medicinal-chemistry program that produced SLU-PP-915 explored a new series of 2,5-disubstituted thiophenes designed as potent estrogen-related receptor agonists.

Researchers found that phenolic or aniline groups within the chemical series could be replaced with a boronic-acid moiety while maintaining ERR activity. Compounds containing this structural feature demonstrated improved metabolic stability in experimental microsomal assays compared with corresponding aniline or phenol compounds.

SLU-PP-915 emerged as one of the potent compounds from this series and was subsequently investigated in gene-expression and in-vivo experiments.

SLU-PP-915 and ERR-Regulated Gene Expression

Published medicinal-chemistry research investigated whether SLU-PP-915 could influence established transcriptional targets of estrogen-related receptor signaling.

In experimental models, SLU-PP-915 significantly upregulated several ERR-associated genes, including PGC-1α, LDHA, DDIT4 and PDK4.

These findings are relevant to the study of ERR-controlled transcriptional networks associated with mitochondrial biology, energy metabolism and exercise-associated cellular responses.

Classification: SLU-PP-915 is most precisely described as a pan-ERR agonist. Changes in PGC-1α expression observed experimentally should not be confused with describing PGC-1α as the compound's direct receptor target.

Why Is SLU-PP-915 Studied as an Exercise Mimetic?

ERRα, ERRβ and ERRγ participate in transcriptional programs associated with mitochondrial function and cellular energy metabolism. These pathways also contribute to skeletal-muscle adaptation to aerobic exercise.

In mouse research, SLU-PP-915 was investigated for its ability to influence exercise-associated gene expression and aerobic exercise capacity. The published work reported increased running distance and duration in the experimental model.

Researchers also examined expression of DNA damage-inducible transcript 4 (Ddit4), an exercise-responsive gene, and reported that SLU-PP-915 could further influence exercise-associated transcriptional responses when studied alongside exercise training.

Research terminology: “exercise mimetic” describes an experimental research concept. Animal exercise-capacity findings do not establish comparable effects or clinical outcomes in humans.

SLU-PP-915 and Mitochondrial Research

Estrogen-related receptors regulate transcriptional programs involved in mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation and cellular energy metabolism.

This connection between ERR signaling and cellular energetics is a major reason SLU-PP-915 is being investigated as an experimental chemical tool in metabolic, mitochondrial and exercise-associated research.

The published literature remains preclinical. Findings from cell-based and animal models do not establish human therapeutic efficacy or safety.

SLU-PP-915 Metabolism Research

Research published in 2026 further characterized SLU-PP-915 using liquid chromatography–high-resolution tandem mass spectrometry and in-vitro metabolic systems involving human liver S9 fractions and human liver microsomes.

Researchers identified seven Phase-I transformation products for SLU-PP-915 in the experimental systems studied. Three selected metabolites were additionally confirmed through chemical synthesis and nuclear magnetic resonance analysis.

These findings contribute to analytical characterization and metabolite identification. In-vitro liver-derived systems do not establish human clinical pharmacokinetics or safety.

Research Comparison

SLU-PP-915 vs SLU-PP-332

Explore the differences in chemistry, ERR pharmacology, oral bioavailability, metabolism and published preclinical evidence.

VIEW COMPARISON →

SLU-PP-915 Research FAQ

What is SLU-PP-915?

SLU-PP-915 is an experimental synthetic small molecule characterized in published research as a pan-estrogen-related receptor agonist.

Is SLU-PP-915 a peptide?

No. SLU-PP-915 is a synthetic small molecule rather than a peptide.

What receptors does SLU-PP-915 target?

Published research characterizes SLU-PP-915 as a pan-ERR agonist with activity across ERRα, ERRβ and ERRγ.

Is SLU-PP-915 orally bioavailable?

Published preclinical research reports oral bioavailability and biological activity for SLU-PP-915 in mice. This does not establish human oral pharmacokinetics or clinical use.

What is the difference between SLU-PP-915 and SLU-PP-332?

They are chemically distinct pan-ERR agonists. One important published distinction is that SLU-PP-915 demonstrated oral bioavailability in mouse research, whereas lack of oral bioavailability was identified as a limitation of SLU-PP-332.

Why is SLU-PP-915 called an exercise mimetic?

Preclinical studies have investigated whether pharmacological ERR activation can reproduce selected molecular responses associated with aerobic exercise. The term describes a research concept and does not establish that the compound substitutes for physical exercise in humans.

Has SLU-PP-915 demonstrated human clinical efficacy?

The published evidence discussed here is preclinical. Animal and laboratory findings do not establish human clinical efficacy, dosing or safety.

Published SLU-PP-915 Research

Hampton CS, et al. (2023). Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915. European Journal of Medicinal Chemistry. PubMed →
Billon C, et al. (2026). An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. Journal of Pharmacology and Experimental Therapeutics. PubMed →
Möller GM, et al. (2026). In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. Rapid Communications in Mass Spectrometry. PubMed →

Research Use Only: SLU-PP-915 is an experimental research compound. This material and the information presented here are intended for laboratory research and scientific-reference purposes only. Published cell-based and animal findings do not establish human dosing, efficacy or safety. Not for human consumption.

SLU-PP-915 Research Compound

SLU-PP-915 Research Compound

What Is SLU-PP-915?

How Does SLU-PP-915 Work in Research Models?